Gensight Biologics (XPAR:SIGHT) COGS-to-Revenue : 0.00 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Gensight Biologics COGS-to-Revenue?

Gensight Biologics's Cost of Goods Sold for the six months ended in Dec. 2023 was €0.00 Mil. Its Revenue for the six months ended in Dec. 2023 was €-0.28 Mil.

Gensight Biologics's COGS to Revenue for the six months ended in Dec. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Gensight Biologics's Gross Margin % for the six months ended in Dec. 2023 was N/A%.

Gensight Biologics COGS-to-Revenue Historical Data

The historical data trend for Gensight Biologics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gensight Biologics COGS-to-Revenue Chart

Gensight Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

Gensight Biologics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Gensight Biologics COGS-to-Revenue Calculation

Gensight Biologics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	1.267
	=	0.00

Gensight Biologics's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	-0.283
	=

Gensight Biologics (XPAR:SIGHT) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Gensight Biologics's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / -0.283
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Gensight Biologics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Gensight Biologics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Gensight Biologics (XPAR:SIGHT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

GSGTF:USA G49N:Germany

Address

74,rue du Faubourg Saint-Antoine, Paris, FRA, 75012

Website

https://www.gensight-biologics.com

Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

Gensight Biologics (XPAR:SIGHT) Headlines

No Headlines